Coherus BioSciences (NASDAQ:CHRS – Get Free Report) is set to issue its quarterly earnings data after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.
Coherus BioSciences (NASDAQ:CHRS – Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.33). The firm had revenue of $77.06 million for the quarter, compared to analyst estimates of $102.00 million. During the same quarter last year, the firm posted ($0.89) EPS. On average, analysts expect Coherus BioSciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Coherus BioSciences Trading Up 1.9 %
NASDAQ:CHRS traded up $0.03 during trading hours on Tuesday, hitting $1.35. 956,456 shares of the company traded hands, compared to its average volume of 2,752,781. Coherus BioSciences has a twelve month low of $1.24 and a twelve month high of $5.47. The firm has a 50-day moving average of $1.64 and a 200 day moving average of $2.07. The stock has a market capitalization of $154.31 million, a price-to-earnings ratio of -1.69 and a beta of 0.60.
Analyst Upgrades and Downgrades
Get Our Latest Research Report on Coherus BioSciences
About Coherus BioSciences
Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.
Featured Stories
- Five stocks we like better than Coherus BioSciences
- Business Services Stocks Investing
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- What Are Dividend Achievers? An Introduction
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- What Are Trending Stocks? Trending Stocks Explained
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.